Last updated: 2026-09-09 04:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vera Therapeutics, Inc. (VERA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $35,29, with a market capitalization of $2,59B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22,72 to $56,05. This page covers its latest market performance, valuation, price trends and company information.
$2,59B | |
$35,80 | |
$56,05 | |
$5,20 | |
$35,89 | |
792,16K | |
2,10M | |
-- | |
$56,05 | |
$22,72 | |
-- | |
-- |
Vera Therapeutics, Inc. (VERA) last closed at $35,89 as of 2026-09-08 23:31:00, unchanged from the previous close of $35,89.
During the latest regular trading session, VERA traded between $5,20 and $56,05, with a volume of 792,16K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Vera Therapeutics, Inc. (VERA) moved from $34,60 to $35,29, representing a gain of 1,98% ($0,68).
The stock traded between $33,18 and $36,70 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1,93 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 37,7%
VERA is currently trading at $35,29, placing it 37,7% of the way from its 52-week low of $22,72 to its 52-week high of $56,05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 361 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vera Therapeutics, Inc. (VERA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.